novo nordisk cagrilintide shares plunge after CagriSema obesity drug trial disappoints Novo Nordisk concludes Phase II
Novo Nordisk concludes Phase II trial of CagriSema for type 2 diabetes A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors. Novo Nordisk announces positive results for CagriSema in type 2 diabetes PMLiVE Cagrilintide vs Retatrutide Compared Dosage Peptide Cagrilintide Peptide 99% Pure Nationwide Peptides
Pay in 4 interest-free payments of $6.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



